SGLT2抑制剂与绝经后出血风险:活性对照新用药者队列研究
基于All of Us研究项目,纳入55-90岁新启用SGLT2抑制剂或DPP-4抑制剂的女性,经倾向评分匹配后比较绝经后出血风险。结果显示SGLT2抑制剂组与DPP-4抑制剂组的PMB风险无显著差异(HR 1.14,95%CI 0.70-1.84),但置信区间较宽且事件数有限,需更大样本验证。
要点
- SGLT2抑制剂新用药者绝经后出血风险与DPP-4抑制剂相比无显著升高。
- 匹配后SGLT2组37例、DPP-4组34例PMB事件,HR 1.14(95%CI 0.70-1.84)。
- 敏感性分析结果与主要分析一致,但事件数有限需谨慎解读。
核心结论
- 与DPP-4抑制剂相比,新启用SGLT2抑制剂未显著增加55-90岁女性的绝经后出血风险。
研究设计与样本
- 活性对照、新用药者队列研究,使用All of Us研究项目数据。
- 纳入2603名55-90岁新启用SGLT2抑制剂或DPP-4抑制剂的女性,其中SGLT2组1328人、DPP-4组1275人。
- 采用倾向评分1:1匹配(按日历时期精确匹配),匹配后650对达到良好协变量平衡。
主要发现
- 匹配队列中,SGLT2组发生37例PMB事件(2248.2人年),DPP-4组发生34例(2374.2人年)。
- SGLT2抑制剂启用与PMB风险无显著关联:HR 1.14(95%CI 0.70-1.84),IRR 1.15(95%CI 0.71-1.87)。
- 敏感性分析结果与主要发现一致。
临床怎么用
- 对于55-90岁女性,启用SGLT2抑制剂时无需因绝经后出血风险担忧而优先选择DPP-4抑制剂。
- 临床中若使用SGLT2抑制剂后出现绝经后出血,仍应按照常规流程评估其他病因。
局限性
- 置信区间较宽,且结局事件数有限,需更大规模研究确认。
- 研究基于All of Us数据库,可能存在未测量混杂和结局 ascertainment 偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Aims A recent case report and pharmacovigilance reports have suggested a possible association between sodium-glucose cotransporter-2 (SGLT2) inhibitors and postmenopausal bleeding (PMB), but population-level evidence is lacking. We evaluated the risk of PMB among women aged 55–90 years initiating SGLT2 inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors. Materials and Methods We conducted an active-comparator, new-user cohort study using data from the All of Us Research Program. Women aged 55–90 years who newly initiated either an SGLT2 inhibitor or a DPP-4 inhibitor were included. The primary outcome was the first recorded PMB during follow-up. Propensity score (PS) matching, with exact matching on calendar period, was used to control for confounding. Hazard ratios (HRs) and incidence rate ratios (IRRs) with 95% confidence intervals (CIs) were estimated using Cox and Poisson regression models. Results Among 2603 women, 1328 initiated SGLT2 inhibitors and 1275 initiated DPP-4 inhibitors. After 1:1 PS matching, 650 pairs achieved good covariate balance. In the matched cohort, 37 and 34 PMB events occurred over 2248.2 and 2374.2 person-years, respectively. SGLT2 inhibitor initiation was not associated with increased PMB risk (HR 1.14, 95% CI 0.70–1.84; IRR 1.15, 95% CI 0.71–1.87). Sensitivity analyses were consistent with the primary findings. Conclusions SGLT2 inhibitor initiation was not associated with a significantly increased PMB risk compared with DPP-4 inhibitor initiation. These findings did not provide evidence of increased PMB risk with SGLT2 inhibitor therapy, although wide confidence intervals and limited outcome events warrant confirmation in larger studies.
引用
- Diabetes, Obesity and Metabolism:SGLT2 Inhibitors and Risk of Postmenopausal Bleeding in Women: An Active‐Comparator, New‐User Cohort Study
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。